Association of sarcopenia with geriatric syndromes and neutrophil / lymphocyte ratio

Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta‐analysis

“…Eighteen studies included subjects with sarcopenia with mean age 80 years and above, 44,45,47,48,[51][52][53]55,56,59,60,[62][63][64]67,[69][70][71] while 11 studies included subjects with sarcopenia with mean age below 80 years. 25,46,49,50,54,57,58,61,65,66,68 Subjects with sarcopenia had a greater prevalence of malnutrition in eight studies as opposed to subjects without sarcopenia [46][47][48]53,55,61,69,71 ; in three studies, they had greater prevalence of general comorbidities 49,56,62 ; in two studies, they had a greater prevalence of depression, 48,67 a higher prevalence of dementia 45,46 and type 2 diabetes 46,50 ; and in one study, they had higher prevalence of osteoporosis 69 and respirat...…”

“…Seventeen studies assessed the prevalence of polypharmacy 25,[45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60] and 13 studies assessed the number of medications received. 44,46,[61][62][63][64][65][66][67][68][69][70][71] The study by Suzan et al was included in the analysis of both groups (prevalence of polypharmacy and number of medications). 46 Detailed characteristics of the included studies are outlined in Tables 1 and 2.…”

“…Five studies were conducted in Japan, 25,47,50,57,69 five in Turkey, 46,55,66,68,70 four in Italy, 44,45,63,67 three in China, 52,53,65 two in Germany, 54,71 two in Australia, 56,60 two in South Korea, 48,51 one in Spain, 62 one in United Kingdom, 49 one in Belgium, 61 one in Taiwan, 59 one in Malaysia 58 and one in multiple European countries. 64 Eighteen studies were cross-sectional [44][45][46][47]50,52,54,55,57,59,[62][63][64][65][66][68][69][70] and six longitudinal, 48,51,53,…”

“…Seventeen studies assessed the prevalence of polypharmacy 25 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 and 13 studies assessed the number of medications received. 44 , 46 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 The study by Suzan et al was included in the analysis of both groups (prevalence of polypharmacy and number of medications). 46 Detailed characteristics of the included studies are outlined in Tables 1 and 2 .…”

“…66 Details regarding the diagnostic criteria for sarcopenia in each study are described in Table 3. Polypharmacy was defined as the use of five or more daily medications in 15 studies, 25,45,46,[48][49][50][51][52][53][54][55][56][57][58][59] six or more in 1 study 60 and four or more in 1 study. 47…”